Tag: triple negative breast cancer
Sacituzumab Govitecan Demonstrates Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2-...
Results from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients...
FDA Approves Sacituzumab Govitecan for Adult Patients with Unresectable Locally Advanced...
This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...
ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan
With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...
Immunomedics Resubmits BLA for Sacituzumab Govitecan
In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
ESMO 2019: Sacituzumab Govitecan Achieves 29 Percent ORR in Advanced Urothelial...
Interim data from a 100-patient cohort of cisplatin-eligible patients participating in the TROPHY-U-01, an international, multi-center, open-label, phase II study, in patients with metastatic...
U.S. Food and Drug Administration Rejects Sacituzumab Govitecan
The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...
Indatuximab Ravtansine Shows Good Tolerability and Signs of Efficacy in Phase...
Results for Phase I/IIa study confirms that indatuximab ravtansine, also known as BT-062, an antibody-drug conjugate being developed by Biotets, offers good tolerability and...
Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...
Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...
Sacituzumab Govitecan Receives Breakthrough Therapy Designation for Triple-negative Breast Cancer
The investigational antibody-drug conjugate, sacituzumab govitecan, also know as IMMU-132 (Immunomedics), has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA)...
Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...
Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...
